06 November 2024 | Wednesday | Company results
Lars Fruergaard Jørgensen
Financial report for the period 1 January 2024 to 30 September 2024
PROFIT AND LOSS | 9M 2024 | 9M 2023 | Growth as reported |
Growth at CER* |
DKK million | ||||
Net sales | 204,720 | 166,398 | 23% | 24% |
Operating profit | 91,602 | 75,808 | 21% | 22% |
Net profit | 72,758 | 61,720 | 18% | N/A |
Diluted earnings per share (in DKK) | 16.29 | 13.71 | 19% | N/A |
* CER: Constant exchange rates (average 2023). |
Lars Fruergaard Jørgensen, president and CEO: "We are pleased with the performance in the first nine months of 2024. The sales growth is driven by increasing demand for our GLP-1-based diabetes and obesity treatments, and we are serving more patients than ever before. Within R&D, we are very pleased about further read-outs across our semaglutide portfolio, including the SOUL trial in people living with diabetes and cardiovascular disease and the ESSENCE trial in people living with MASH."
© 2024 Biopharma Boardroom. All Rights Reserved.